Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20067118 | 0.86 | CYP1A2 (0.50) | CYP1A2SLC13A5CYP2A6MMP1MMP9 | |
| SCHEMBL8939501 | 0.83 | CYP1A2 (0.62) | CYP1A2SLC13A5CYP2A6MMP1MMP9 | |
| SCHEMBL29982408 | 0.83 | CYP1A2 (0.62) | CYP1A2SLC13A5CYP2A6MMP1MMP9 | |
| SCHEMBL8872531 | 0.82 | CYP1A2 (0.53) | CYP1A2SLC13A5CYP2A6FFAR1PDPK1 | |
| SCHEMBL12802204 | 0.80 | CYP1A2 (0.46) | CYP1A2CYP2A6PPARAMMP1MMP9 | |
| SCHEMBL20347157 | 0.80 | SLC13A5 (0.45) | CYP1A2SLC13A5CYP2A6PPARAMMP1 | |
| SCHEMBL14740848 | 0.80 | CYP1A2 (0.45) | CYP1A2SLC22A12PPARASLC6A2 | |
| SCHEMBL16595187 | 0.79 | CYP1A2 (0.50) | CYP1A2SLC13A5CYP2A6FFAR1PDPK1 | |
| SCHEMBL517462 | 0.79 | SMN1; SMN2 (0.57) | CYP1A2PPARACYP2D6SLC6A2 | |
| SCHEMBL16005357 | 0.79 | CYP1A2 (0.46) | CYP1A2SLC13A5CYP2A6PPARAMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| CN-115698292-A | Aptamers binding to thiamine analogs and derivatives | 梅里特斯英国第二有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220323449-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | MEI PHARMA, INC. | 2022-10-13 | — | — | US | disclosed |
| US-11400097-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| CN-107501241-B | Compounds, pharmaceutical compositions containing them and their use in the treatment of proliferative diseases | 梅制药公司 | 2020-10-13 | — | — | CN | disclosed |
| US-20200316080-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | MEI PHARMA, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10603324-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10335415-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190083506-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | PATHWAY THERAPEUTICS, INC. | 2019-03-21 | — | — | US | disclosed |
| US-10064868-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20120252802-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | PATHWAY THERAPEUTICS INC. (US) | 2012-10-04 | — | — | US | disclosed |
| WO-2012135160-A1 | (ALPHA- SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5 -TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THESE COMPOUNDS FOR USE IN TREATING PROLIFERATIVE DISEASES | PATHWAY THERAPEUTICS INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-1308436-B1 | CALCIUM RECEPTOR ANTAGONISTS | JAPAN TOBACCO INC (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7211685-B2 | Calcium receptor antagonists | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-7211685-B2 | Calcium receptor antagonists | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-7211685-B2 | Calcium receptor antagonists | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-6916956-B2 | Calcium receptor antagonist | JAPAN TOBACCO, INC. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20050107448-A1 | Calcium receptor antagonists | JAPAN TABACCO INC. | 2005-05-19 | — | — | US | disclosed |
| US-20040006130-A1 | Calcium receptor antagonist | JAPAN TOBACCO INC (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1308436-A1 | CALCIUM RECEPTOR ANTAGONISTS | JAPAN TOBACCO INC. (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316080-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | CYP1A2 224/4885SLC13A5 2790/4885CYP2A6 962/4885 |
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | CYP1A2 224/4885SLC13A5 2790/4885CYP2A6 962/4885 |
| US-20220323449-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | CYP1A2 224/4885SLC13A5 2790/4885CYP2A6 962/4885 |
| US-20120252802-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | CYP1A2 224/4885SLC13A5 2790/4885CYP2A6 962/4885 |
| US-10335415-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | CYP1A2 224/4885SLC13A5 2790/4885CYP2A6 962/4885 |
| US-10603324-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | CYP1A2 224/4885SLC13A5 2790/4885CYP2A6 962/4885 |
| US-20050107448-A1 | Calcium receptor antagonists | CASR, CALCR, CALCRL | CYP1A2 1943/4885SLC13A5 735/4885CYP2A6 236/4885 |
| US-10064868-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | CYP1A2 224/4885SLC13A5 2790/4885CYP2A6 962/4885 |
| US-20040006130-A1 | Calcium receptor antagonist | CALCRL, CASR, CALCR | CYP1A2 2060/4885SLC13A5 905/4885CYP2A6 159/4885 |
| US-20190083506-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | CYP1A2 224/4885SLC13A5 2790/4885CYP2A6 962/4885 |
| US-11400097-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | CYP1A2 224/4885SLC13A5 2790/4885CYP2A6 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.